US STOCKS · SEC COMPANY PROFILE
Johnson & Johnson
JOHNSON & JOHNSON · NYSE
Johnson & Johnson sells innovative medicines and medical technology products across pharmaceutical and healthcare markets.
Visit Johnson & Johnson’s official websiteReported revenue spread evenly through elapsed UTC time. Refresh does not restart it; it resets at midnight UTC.
For every $100 of reported revenue
2025-12-29–2026-09-27 · ratios from the same reported period
Profit includes accounting items that may not involve cash today. Operating cash flow measures cash from operations; capital spending covers the reported investment measure. These ratios help compare scale, but industry, seasonality and one-time items still matter. They are not a breakdown that adds to $100.
Two operating segments
Q3 reported net earnings include $5.780 billion of other expense, net, in the statement of earnings. Profit is not cash collected and can include large one-time items; compare the source notes before extrapolating. Segment shares are calculated from consolidated revenue for the same period.
JNJ stock price
TradingView supplies updated market data automatically. The chart starts with one-hour intervals; the current interval can change as trades arrive. Exchange delays and availability are shown by the provider.
WORLD NUMBERS ASSESSMENTCompany Health Score
Expand for the score breakdown and outlookSolid overall healthCash, growth, profits and investment · review the assumptions below7/10View details
Company Health Score
Expand for the score breakdown and outlookSolid overall health
Our assessment of the reported financial position and the company-specific outlook.
Higher means stronger overall financial health under this model. This is World Numbers’ subjective assessment, not an official rating or a prediction of the stock price. It does not establish that shares are good value.
$16.91B cash and equivalents against $115.9B total liabilities. This excludes marketable investments.
5.9% change in latest-quarter revenue from the comparable year-earlier quarter.
14.7% net margin for the reported 273-day period. One-time gains or charges can affect this measure.
$15.12B operating cash flow after cash capital spending for the same reported period. This is a calculation, not all investing or financing activity.
New medicines and medical technology can support growth; patent expirations, clinical outcomes, litigation and portfolio changes create uncertainty.
Looking ahead
New medicines and medical technology can support growth; patent expirations, clinical outcomes, litigation and portfolio changes create uncertainty. This is a speculative editorial interpretation of the filing’s business and risk discussion, not quantified issuer guidance.
How we arrived at the score
Cash scores use cash ÷ liabilities: at least 0.5 scores 9, 0.25 scores 8, 0.1 scores 6; otherwise 4. Revenue growth scores: at least 30% scores 9, 10% scores 8, non-negative scores 6; otherwise 3. Net margin scores: at least 20% scores 9, 10% scores 8, non-negative scores 6; otherwise 3. Cash after investment ÷ revenue scores: at least 15% scores 9, 5% scores 8, non-negative scores 6; otherwise 3. Future outlook is an editorial score. The weighted result is 7.15, rounded to 7. These thresholds and weights are judgment choices, not statistically validated probabilities. The assessment uses data through 2026-09-27; it does not update each second.
Net income
Latest quarter: $210M net income · 0.8% net margin
Q1 2027 at this pace: $3,619,450,549Reported total ÷ 273 days × elapsed UTC time. Refresh does not restart this estimate; it resets at midnight UTC.Operating cash flow
Reported cash flow from operations
Q1 2027 at this pace: $6,214,285,714Reported total ÷ 273 days × elapsed UTC time. Refresh does not restart this estimate; it resets at midnight UTC.Capital spending
Cash purchases of property, plant and equipment; acquisitions and financing are separate.
Q1 2027 at this pace: $1,230,329,670Reported total ÷ 273 days × elapsed UTC time. Refresh does not restart this estimate; it resets at midnight UTC.Current leadership
Joaquin Duato
Chief executive officer
Leadership is checked separately from annual compensation. The historical pay table below may cover different roles or former executives.
Leadership check and financial reporting dates are separate. Annual total compensation is updated when a new compensation disclosure is published; quarterly earnings do not necessarily include it.
Reported executive pay
Three executives from the dated compensation disclosure. Names, roles and pay below describe that disclosure and do not establish who leads the company today.
Why use this pay period? The latest reviewed proxy reports fiscal 2025 annual compensation. A filing published in 2026 can describe the preceding completed pay year. These counters illustrate reported annual pay; they do not measure current payroll.
Joaquin Duato
Historical disclosure: CEO
- Salary reported · 2025
- $1,600,000
- Total pay reported · 2025
- $32,758,111
- Shares held or eligible to buy
- 1,407,667
- Current value of reported shares
- Not calculated The chart’s quote is provided separately. We do not multiply historical ownership by an unverified price or treat conditional awards as cash.
Total reported compensation includes the filing’s grant-date stock or option values, cash incentives, benefits and any pension adjustments; it is not all cash received.
Joseph Wolk
Historical disclosure: CFO
- Salary reported · 2025
- $1,240,646
- Total pay reported · 2025
- $14,405,442
- Shares held or eligible to buy
- 548,708
- Current value of reported shares
- Not calculated The chart’s quote is provided separately. We do not multiply historical ownership by an unverified price or treat conditional awards as cash.
Total reported compensation includes the filing’s grant-date stock or option values, cash incentives, benefits and any pension adjustments; it is not all cash received.
Jennifer Taubert
Historical disclosure: Innovative medicine leader
- Salary reported · 2025
- $1,220,308
- Total pay reported · 2025
- $14,030,063
- Shares held or eligible to buy
- 748,339
- Current value of reported shares
- Not calculated The chart’s quote is provided separately. We do not multiply historical ownership by an unverified price or treat conditional awards as cash.
Total reported compensation includes the filing’s grant-date stock or option values, cash incentives, benefits and any pension adjustments; it is not all cash received.
Total compensation can include grant-date accounting values of stock or options and benefits. It is not necessarily cash received. Ownership date: 2026-02-24. Beneficial ownership can include exercisable options and restricted shares; it is not the same as current tradable stock.
Employees
The annual report employee count and proxy compensation population can differ in measurement date and inclusion of temporary or part-time staff. Median pay is rounded to the nearest $1,000 and is a conservative estimate. The issuer CEO ratio adds healthcare benefits to the compensation-table total. The 140,800 count is people; the annual filing separately reports 138,200 full-time equivalent positions. Employee counts are reported snapshots and do not tick. Companies use different employee populations and pay-ratio methods, so comparisons need care.
Revenue & net income
Revenue appears in blue above net income in pink. Net margin is net income divided by revenue. These are reported results, not estimates.
2025-09-28
2026-09-27
What changed?
$25.4B versus $23.99B in the comparable quarter a year earlier. The dollar change was $1.41B.
$210M net income versus $5.15B a year earlier. Net income includes expenses and other gains or charges; it is not a measure of cash in the bank.
Q3 reported net earnings include $5.780 billion of other expense, net, in the statement of earnings. Profit is not cash collected and can include large one-time items; compare the source notes before extrapolating. For the 273-day cash-flow period, operating cash flow less cash capital spending was $15.12B.
Watch next quarter
New medicines and medical technology can support growth; patent expirations, clinical outcomes, litigation and portfolio changes create uncertainty. Next earnings date: consult the company’s confirmed announcements; no unverified calendar date is displayed.
What was reported at 2026-09-27
Balances update when a new filing is verified. Investment categories differ; only the labeled short-term category is displayed.
Valuation, returns & earnings
Capital returns & voting rights
Cash dividends and repurchases are historical payments. Future authorizations and market price are separate from those cash flows.
Beneficial ownership can include exercisable options and restricted shares; it is not the same as current tradable stock. Reported executive ownership is dated 2026-02-24; balances and market values are different measures.
Johnson & Johnson financial questions, explained
How much revenue does Johnson & Johnson generate per day and per second?
The reviewed SEC filing reports $74,771,000,000 of revenue for 2025-12-29 through 2026-09-27, an actual 273-day period. That is $273,886,447 per day or $3,169.98 per second when spread evenly. The counter illustrates historical scale; it is not live sales, issuer guidance or a forecast.
Read the SEC sourceWhat were Johnson & Johnson’s latest quarterly revenue and earnings?
For the quarter 2026-06-29 through 2026-09-27, revenue was $25,399,000,000 and reported net income was $210,000,000, a 0.8% net margin. The same filing presents $23,993,000,000 of revenue and $5,152,000,000 of net income for the comparable quarter ended 2025-09-28. Q3 reported net earnings include $5.780 billion of other expense, net, in the statement of earnings. Profit is not cash collected and can include large one-time items; compare the source notes before extrapolating.
Read the SEC sourceWhere does Johnson & Johnson’s reported revenue come from?
Two operating segments: Innovative Medicine: $48,567,000,000 (65.0%); MedTech: $26,204,000,000 (35.0%). These figures cover 2025-12-29 through 2026-09-27. Q3 reported net earnings include $5.780 billion of other expense, net, in the statement of earnings. Profit is not cash collected and can include large one-time items; compare the source notes before extrapolating.
Read the SEC sourceHow much compensation did Joaquin Duato report at Johnson & Johnson?
The latest reviewed proxy reports $1,600,000 salary and $32,758,111 total compensation for fiscal 2025. CEO. Total reported compensation includes the filing’s grant-date stock or option values, cash incentives, benefits and any pension adjustments; it is not all cash received. The annual-pay counter is an illustration spread through the current calendar year, not evidence of cash being paid every second.
Read the SEC sourceHow many employees does Johnson & Johnson report, and what is median pay?
The annual filing reports 140,800 employees as of 2025-12-28. The proxy reports median total employee compensation of $91,000 for Fiscal 2025. Median means the middle employee in the disclosed population, not an average base salary. The annual report employee count and proxy compensation population can differ in measurement date and inclusion of temporary or part-time staff. Median pay is rounded to the nearest $1,000 and is a conservative estimate. The issuer CEO ratio adds healthcare benefits to the compensation-table total. The 140,800 count is people; the annual filing separately reports 138,200 full-time equivalent positions.
Read the SEC sourceDoes Johnson & Johnson’s operating cash flow cover reported capital spending?
For 2025-12-29 through 2026-09-27, reported operating cash flow was $18,850,000,000 and cash capital spending was $3,732,000,000. Subtraction leaves $15,118,000,000. Cash purchases of property, plant and equipment; acquisitions and financing are separate. This calculation excludes other investing and financing activity and differs from net income.
Read the SEC sourceDoes Johnson & Johnson pay a cash dividend?
The reviewed 2025-12-29 through 2026-09-27 period shows $9,585,000,000 of cash dividend payments. Cash dividends and repurchases are historical payments. Future authorizations and market price are separate from those cash flows.
Read the SEC sourceWhat should investors watch in Johnson & Johnson’s next report?
Watch Innovative Medicine versus MedTech sales, Patent expiration and new products, Litigation and acquisition effects. New medicines and medical technology can support growth; patent expirations, clinical outcomes, litigation and portfolio changes create uncertainty. The next-quarter counters hold the reported daily rate unchanged. They are World Numbers scenarios, not issuer guidance or stock-price predictions.
Read the SEC sourceReporting period: 2025-12-29–2026-09-27 · filed 2026-10-21 · last completed verification 2026-10-22 · page updated 2026-10-26
How World Numbers calculates estimatesHow the estimates work
We divide each reported flow by its actual 273-day reporting period. The daily rate is spread evenly over elapsed UTC time and resets at midnight. Refreshing the page does not restart the counter. The next-calendar-quarter illustration holds that pace unchanged; it is not live sales or a company forecast. Annual executive pay is spread across the current calendar year, including leap-year day counts. Stock awards, balances, employees and shares are not current payroll or live counts. Company-specific limitations: Q3 reported net earnings include $5.780 billion of other expense, net, in the statement of earnings. Profit is not cash collected and can include large one-time items; compare the source notes before extrapolating.